Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

DURECT Corporation DRRX NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
46/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

DURECT Corporation (DRRX) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 8 Buy, 5 Hold.

DRRX Analyst Ratings

Buy
13
Ratings
8 Buy
5 Hold
Based on 13 analysts giving stock ratings to DURECT Corporation in the past 3 months
Rating breakdown
Buy
8 62%
Hold
5 38%
62%
Buy
8 analysts
38%
Hold
5 analysts
0%
Sell
0 analysts

People Also View

NBIX
NBIX
Neurocrine Biosciences, Inc.
$131.44
+0.48%
 ALKS
ALKS
Alkermes plc
$33.22
-1.92%
 DCPH
DCPH
Deciphera Pharmaceuticals, Inc.
$25.59
+0.08%
 AVDL
AVDL
Avadel Pharmaceuticals plc
$21.64
+0.00%
 TARO
TARO
Taro Pharmaceutical Industries Ltd.
$42.98
+0.01%
 COLL
COLL
Collegium Pharmaceutical, Inc.
$34.93
-1.99%
 IRWD
IRWD
Ironwood Pharmaceuticals, Inc.
$4.37
+8.17%
 AQST
AQST
Aquestive Therapeutics, Inc.
$4.24
+2.17%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message